Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott reported Q4 2021 sales of $11.5 billion, marking a 7.2% increase, driven by COVID-19 testing sales of $2.3 billion. For the full year, GAAP diluted EPS rose to $3.94, with adjusted EPS at $5.21, a 42.7% growth year-over-year. Abbott projects 2022 diluted EPS guidance of at least $3.43, with adjusted EPS of at least $4.70. The company also declared a quarterly dividend of $0.47 per share, continuing its 50-year dividend growth streak.
Abbott has received FDA clearance for its EnSite X EP System with EnSite Omnipolar Technology, a new cardiac mapping platform aimed at treating abnormal heart rhythms in the U.S. and Europe. The system utilizes a proprietary Advisor HD Grid Catheter to create detailed 3D maps of the heart, enhancing treatment precision for conditions such as atrial fibrillation. This innovative technology combines unipolar and bipolar measurement principles, enabling upgradable software for continuous advancements in patient care.
On January 11, 2022, ACELYRIN, INC. appointed Melanie Gloria as the new Chief Operating Officer (COO). With over 20 years in biotechnology, Gloria previously held senior roles at Abbott, AbbVie, and Horizon Therapeutics, leading R&D functions and achieving global therapy approvals. Her extensive background in drug development includes multiple therapeutic areas such as oncology and immunology. The leadership team believes Gloria's experience will enhance ACELYRIN's pursuit of life-changing treatments and support its growth strategy.
Abbott (NYSE: ABT) made history as the first healthcare company to present a keynote at CES, led by CEO Robert B. Ford. The keynote titled "Human-Powered Health" highlighted Abbott's vision of using technology to empower individuals in healthcare management. A key announcement was the development of Lingo, a new category of consumer biowearables designed to monitor various health indicators such as glucose and ketones. Abbott aims to enhance personal health management and improve athletic performance through these innovative devices.
Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on January 26, 2022, prior to market opening. A live webcast of the earnings call is scheduled for 8 a.m. Central and will be available on Abbott's Investor Relations website. Abbott is a global healthcare leader with a diverse portfolio in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries through its 109,000 employees.
Abbott (NYSE: ABT) announced FDA approval for expanded MRI compatibility of its Proclaim™ XR Spinal Cord Stimulation (SCS) System with Octrode™ leads. This new labeling reduces MRI restrictions, allowing lead tips to be placed anywhere on the spine and increasing radiofrequency power usage during scans. Patients will benefit from faster and higher-quality MRI scans, addressing significant challenges in imaging for those with implanted devices. This update improves access to MRI imaging for existing patients and enhances diagnoses for complex conditions.
Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8 a.m. Central time. Robert B. Ford, the CEO, will lead the presentation. A live webcast will be available on Abbott's Investor Relations website, with an archived version posted later that day. Abbott is recognized as a global healthcare leader, providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. The company serves over 160 countries with a workforce of 109,000 colleagues.
Abbott (NYSE: ABT) has appointed Robert B. Ford as the new Chairman of the Board, effective immediately, following the retirement of Miles D. White after 38 years with the company. The transition is expected to bolster Abbott’s leadership in health technology, with Ford committed to advancing the company's mission amidst ongoing opportunities in healthcare. White praised Abbott's transformation during his tenure, while Ford expressed gratitude for White's mentorship. Abbott operates globally in diagnostics, medical devices, nutritionals, and branded generic medicines.
Abbott has announced a 4.4% increase in its quarterly common dividend, raising it to 47 cents per share, marking the 50th consecutive year of dividend growth. This payment will be made on Feb. 15, 2022, to shareholders on record by Jan. 14, 2022. The company also authorized a new $5 billion share repurchase program, supporting its strategy for sustainable shareholder returns and innovation. Abbott boasts a history of 392 consecutive quarterly dividends and is a member of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) has launched Similac 360 Total Care, the first U.S. infant formula featuring a unique blend of five human milk oligosaccharides (HMOs) to support overall baby health, immune system, and brain development. This formula addresses the needs of the nearly 75% of parents using infant formula within the first six months due to various reasons. With over 20 years of research on HMOs, Abbott aims to narrow the gap between breast milk and formula, offering parents a scientifically backed alternative to nourish their babies.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
